Risk factors for venous thromboembolic events in cancer patients

Annals of Oncology

Volumn 17, Issue 2, 2006, Pages 297-303

  Kröger, Knut ^a   Weiland, D ^a   Ose, C ^a   Neumann, N ^a   Weiss, S ^a   Hirsch, C ^a   Urbanski, K ^a   Seeber, S ^a   Scheulen, M E ^a  

^a UNIVERSITY OF ESSEN MEDICAL SCHOOL   (Germany)

Author keywords

Cancer; Chemotherapy; Deep vein thrombosis; Risk assessment

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; ANTITHROMBIN III; C REACTIVE PROTEIN; CHLORMETHINE; HEPARIN; LACTATE DEHYDROGENASE; PODOPHYLLOTOXIN; PYRIMIDINE DERIVATIVE; VINCA ALKALOID;

ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE; FEVER; FOLLOW UP; GEOGRAPHIC DISTRIBUTION; GERMANY; HIGH RISK POPULATION; HUMAN; INFECTION; LUNG EMBOLISM; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; POPULATION DISTRIBUTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; VENOUS THROMBOEMBOLISM; VOMITING;

EID: 31544478042     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdj068     Document Type: Article

References (26)

1. Goldhaber SZ, Tapson VF. DVT FREE Steering Committee. A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. Am J Cardiol 2004; 93: 259-262.
2. Prandoni P. Cancer and thromboembolic disease: How important is the risk of thrombosis? Cancer Treat Rev 2002; 28: 133-136.
3. Bergqvist D, Agnelli G, Cohen AT et al. ENOXACAN II Investigators. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002; 346: 975-980.
4. Samama MM, Cohen AT, Darmon JY et al. A comparison of enoxaparin with placebo for the prevention of venous thrombembolism in acutely ill medical patients. N Eng J Med 1999; 341: 793-800.
5. Geerts WH, Heit JA, Clagett GP et al. Prevention of venous thromboembolism. Chest. 2001; 119 (Suppl 1): 132S-175S.
6. Kakkar AK, Levine MN, Kadziola Z et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: The fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004; 22: 1944-1948.
7. Lee AY. Epidemiology and management of venous thromboembolism inpatients with cancer. Thromb Res 2003; 110: 167-172.
8. Falanga A, Zacharski L. Deep vein thrombosis in cancer: The scale of the problem and approaches to management. Ann Oncol 2005; 16: 696-701.
9. Lee AY. Anti-thrombotic therapy in cancer patients. Expert Opin Pharmacother 2003; 4: 2213-2220.
10. Deitcher SR. Cancer-related deep venous thrombosis: Clinical importance, treatment challenges, and management strategies. Semin Thromb Hemost 2003; 29: 247-258.
11. Mandala M, Ferretti G, Cremonesi M et al. Venous thromboembolism and cancer: New issues for an old topic. Crit Rev Oncol Hematol 2003; 48: 65-80.
12. Geerts WH, Pineo GF, Heit JA et al. Prevention of venous thromboembolism. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (Suppl 3): 338S-400S.
13. Bick RL, Strauss JF, Frenkel EP. Thrombosis and hemorrhage in oncology patients. Hematol Oncol Clin North Am 1996; 10: 875-907.
14. Kurz X, Kahne SR, Abenhaim L et al. Chronic venous disorders of the leg: epidemiology, outcomes, diagnosis and management. Int Angiol 1999; 18: 83-102.
15. Ronning M, Blix HS, Harbo BT et al. Different versions of the anatomical therapeutic chemical classification system and the defined daily dose - are drug utilisation data comparable? Eur J Clin Pharmacol 2002; 56: 723-727.
16. National Cancer Institute. Common Toxicity Criteria, Version 2.0. Bethesda, Maryland.
17. Lee AY, Levine MN, Baker RI et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146-153.
18. Meyer G, Marjanovic Z, Valcke J et al. Comparison of law-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism inpatients with cancer: A randomized controlled study. Arch Intern Med 2002; 162: 1729-1735.
19. Heit JA, Silverstein MD, Mohr DN et al. Risk factors for deep vein thrombosis and pulmonary embolism. Arch Intern Med 2000; 160: 809-815.
20. Sallah S, Wan JY, Nguyen NP. Venous thrombosis in patients with solid tumors: Determination of frequency and characteristics. Thromb Haemost 2002; 87: 575-579.
21. Levine MN. Prevention of thrombotic disorders in cancer patients undergoing chemotherapy. Thromb Haemost 1997; 78: 133-136.
22. Mills PJ, Parker B, Jones V et al. The effects of standard anthracycline-based chemotherapy on soluble ICAM-1 and vascular endothelial growth factor levels in breast cancer Clin Cancer Res 2004; 10: 4998-5003.
23. Behrendt CE, Ruiz BB. Venous thromboembolism among patients with advanced lung cancer randomized to prinomastat or placebo, plus chemotherapy. Thromb Haemost 2003; 90: 734-737.
24. Weill-Engerer S, Meaume S, Lahlou A et al. Risk factors for deep vein thrombosis in inpatients aged 65 and older: A case-control multicenter study. J Am Geriatr Soc 2004; 52: 1299-1304.
25. Kazmers A, Groehn H, Meeker C. Do patients with acute deep vein thrombosis have fever? Am Surg 2000; 66: 598-601.
26. Bucek RA, Reiter M, Quehenberger P et al. C-reactive protein in the diagnosis of deep vein thrombosis. Br J Haematol 202; 119: 385-389.